Switzerland· 66417008
Rosuvastatin-Mepha
A rosuvastatin product, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Rosuvastatin is registered in 18 of 19 countries.
Countries holding a registration under ATC C10AA07 (rosuvastatin), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 11 of them publish a price we can compare per daily dose
Rosuvastatin · ATC C10AA07
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rosuvastatin costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.036 in United States to $0.73 in Switzerland — a ×20 gap.
- Switzerland: $0.73 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Rosuvastatin · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.73
- ES Spain$0.39
- IT Italy$0.26
- FR France$0.17
- US United States$0.036 (acquisition cost)
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- C10AA07
- ATC class
- Rosuvastatin
- Defined daily dose
- 10 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- gtin7680664170085Blist 100 Stk (alt)CHF 59.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
689 interactions on record for rosuvastatin.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rosuvastatin · interactions on record
689 records
- 29 severe
- 200 moderate
- 20 minor
- 403 info
Most severe, free to view
- ClofibrateC10AB01severe
- GemfibrozilC10AB04severe
- FenofibrateC10AB05severe
- MipomersenC10AX11severe
37 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C10AA07
Rosuvastatin, as other registers publish it.
- CanadaACH-ROSUVASTATINACCORD HEALTHCARE INC
- CanadaACH-ROSUVASTATINACCORD HEALTHCARE INC
- CanadaACH-ROSUVASTATINACCORD HEALTHCARE INC
- CanadaACH-ROSUVASTATINACCORD HEALTHCARE INC
- CanadaAG-ROSUVASTATIN CALCIUMANGITA PHARMA INC.
- CanadaAG-ROSUVASTATIN CALCIUMANGITA PHARMA INC.
- CanadaAG-ROSUVASTATIN CALCIUMANGITA PHARMA INC.
- CanadaAG-ROSUVASTATIN CALCIUMANGITA PHARMA INC.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c63b03d8-3470-407b-ba00-e808de3402f8 GET /v1/drugs/c63b03d8-3470-407b-ba00-e808de3402f8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "rosuvastatinum 20 mg",
"valid_from": "2017-07-01",
"limitations": "[{\"description\":\"Bei Erwachsenen ab 18 bis und mit 75 Jahren wird eine Behandlung mit Statinen vergütet im Rahmen der Sekundärprävention kardiovaskulärer Ereignisse sowie im Rahmen der Primärprävention bei Personen mit hohem oder sehr hohem Risiko nach AGLA-Risikokategorie sowie bei Personen mit einem Risiko von über 1% nach AGLA-Risikokategorie. Eine entsprechend bis und mit 75 Jahren gestartete Statin-Therapie wird auch nach Vollendung des 75. Lebensjahres weiter vergütet.<br>\\nBei Personen über 75 Jahren wird eine neu beginnende Statin-Therapie nur vergütet im Rahmen der Sekundärprävention kardiovaskulärer Ereignisse sowie im Rahmen der Primärprävention bei Personen mit hohem oder sehr hohem Risiko nach AGLA-Risikokategorie.<br>\\nRosuvastatin-Mepha wird zudem vergütet bei Knaben und Mädchen (mindestens ein Jahr postmenarchal) im Alter von 10-17 Jahren mit heterozygoter familiärer Hypercholesterinämie, als Zusatz zu Diät, wenn Diät und andere nicht pharmakologische Massnahmen (z.B. Bewegung, Gewichtsreduktion) nicht ausreichend sind.<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2022-08-01\"}]",
"galenic_form": "Filmtabl 20 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2017-07-01",
"self_retention_pct": 10
}See everything about rosuvastatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.